Events and announcements

Canada’s National Guideline for the Clinical Management of Opioid Use Disorder (OUD) has been updated to reflect the latest literature.

TB epidemic is still a global problem: the World Health Organization (WHO) has released the Global tuberculosis report 2024 based on 2023 data.

A new article in the Harm Reduction Journal, co-authored by UIPHP researchers, highlights the sustainability of opioid agonist therapy (OAT) programmes in the context of the transition from donor support to national funding in 4 countries of the EECA region: Belarus, the Republic of Moldova, Tajikistan, and Ukraine.

The World Health Organization has released updated guidelines on TB preventive treatment.

A new report of the Joint United Nations Programme on HIV/AIDS (UNAIDS) on the HIV/AIDS epidemic in the world as of 2024 has been published.

The DrugUsersNews channel has published a new documentary film with the participation of UIPHP experts and many of our partners and colleagues on the implementation and expansion of the OAT program in Ukraine.

Researchers of the Ukrainian Institute on Public Health Policy and our partners from Yale University presented the results of two projects related to the implementation of OAT programs in Ukraine.

On July 22, at the 25th International AIDS Conference – AIDS 2024, which takes place from 22 to 26 July, 2024 in Munich, Germany, the session "Person-centred and integrated healthcare and harm reduction services for people living with and affected by HIV, hepatitis C and tuberculosis in Eastern Europe and Central Asia (EECA)" was held.

On June 19, 2024, we held the final ECHO session of the seven-year research project "Integrating Addiction Treatment and HIV Services into Primary Care Clinics in Ukraine", which aimed to study the effectiveness of the integrated model of health care services in primary care clinics and interventions to improve the quality of health care services through the training of physicians.

The expert evidence indicated that co-administering MDR-TB and HCV treatments, as compared to delaying HCV treatment while treating MDR-TB alone, may yield several benefits.